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CONSPECTUS: Enzymes have evolved to catalyze a range of biochemical trans-
formations with high efficiencies and unparalleled selectivities, including stereoselectivities,
regioselectivities, chemoselectivities, and substrate selectivities, while typically operating
under mild aqueous conditions. These properties have motivated extensive research to
identify or create enzymes with reactivity that complements or even surpasses the
reactivity of small-molecule catalysts for chemical reactions. One of the limitations
preventing the wider use of enzymes in chemical synthesis, however, is the narrow range of
bond constructions catalyzed by native enzymes. One strategy to overcome this limitation
is to create artificial metalloenzymes (ArMs) that combine the molecular recognition of
nature with the reactivity discovered by chemists.
This Account describes a new approach for generating ArMs by the formal replacement of
the natural iron found in the porphyrin IX (PIX) of hemoproteins with noble metals.
Analytical techniques coupled with studies of chemical reactivity have demonstrated that
expression of apomyoglobins and apocytochrome P450s (for which “apo-” denotes the
cofactor-free protein) followed by reconstitution with metal−PIX cofactors in vitro creates proteins with little perturbation of
the native structure, suggesting that the cofactors likely reside within the native active site. By means of this metal substitution
strategy, a large number of ArMs have been constructed that contain varying metalloporphyrins and mutations of the protein.
The studies discussed in this Account encompass the use of ArMs containing noble metals to catalyze a range of abiological
transformations with high chemoselectivity, enantioselectivity, diastereoselectivity, and regioselectivity. These transformations
include intramolecular and intermolecular insertion of carbenes into C−H, N−H, and S−H bonds, cyclopropanation of
vinylarenes and of internal and nonconjugated alkenes, and intramolecular insertions of nitrenes into C−H bonds. The rates of
intramolecular insertions into C−H bonds catalyzed by thermophilic P450 enzymes reconstituted with an Ir(Me)−PIX cofactor
are now comparable to the rates of reactions catalyzed by native enzymes and, to date, 1000 times greater than those of any
previously reported ArM. This reactivity also encompasses the selective intermolecular insertion of the carbene from ethyl
diazoacetate into C−H bonds over dimerization of the carbene to form alkenes, a class of carbene insertion or selectivity not
reported to occur with small-molecule catalysts. These combined results highlight the potential of well-designed ArMs to
catalyze abiological transformations that have been challenging to achieve with any type of catalyst. The metal substitution
strategy described herein should complement the reactivity of native enzymes and expand the scope of enzyme-catalyzed
reactions.
1. INTRODUCTION
The site-selective and stereoselective synthesis of organic
molecules catalyzed by transition−metal complexes has been a
major focus of many research groups, including ours.1 However,
one difficulty faced when developing catalysts based tran-
sition−metal complexes is to control the position and
orientation of the substrate and to evolve and modify these
catalysts in an iterative fashion to control reactivity and
selectivity.
In parallel, our research group and others have investigated
the potential of artificial metalloenzymes (ArMs) to be used for
the synthesis of organic molecules, in many cases for the
synthesis of enantioenriched products.2,3 One difference
between small-molecule catalysts and enzymes is the innate
specificity of the enzymatic system for a native substrate and the
ability of the catalyst to be readily evolved to react with similarly
high selectivity for non-native substrates.2,4,5 This ability to
evolve enzymes for non-native functions was the subject of the
2018 Nobel Prize.
To illustrate this point, we highlight the oxidation of organic
molecules catalyzed by P450 enzymes. Through the course of
natural evolution, cytochrome P450s have evolved to oxidize a
wide array of molecules. Some P450 enzymes catalyze
hydroxylation of a narrow scope of substrates with high
regioselectivity and stereoselectivity; other P450s catalyze
reactions of a broad scope of substrates with low selectivity as
part of biological detoxification processes.6,7 Through labo-
ratory evolution, the site selectivity and enantioselectivity of
these enzymes can be altered and controlled.8−10 Moreover, the
activities of certain P450 enzymes toward reactions other than
hydroxylation can be tuned by directed evolution.4
A portion of our research group has been interested in
combining the broad range of reactions catalyzed by transition
metal complexes with the high selectivity and potential for
evolution of a protein scaffold. If these systems could be
combined in a productive fashion, then enzymes could catalyze
the formation of C−N, C−C, and C−X (X = halogen) bonds
between diverse functional groups. For example, if P450
enzymes could catalyze the formation of C−C bonds from
C−H bonds, rather than being restricted to their natural
formation of C−O bonds from C−H bonds, then these systems
could be used for many synthetic applications.
Several research groups have been interested in creating ArMs
that catalyze abiological reactions.2 Ward first devoted a
concerted effort to this goal by applying biotin−streptavidin
complexation to create catalysts for a wide range of reactions
catalyzed by transition−metal complexes tethered to biotin.11
This versatile supramolecular anchoring has been used by Ward
and co-workers to create abiological metalloenzymes that
catalyze allylic alkylation, ring-closing metathesis, hydrogena-
tion, and annulation.12,13 Many others who have contributed to
this virtual special issue have used alternative hosts, unnatural
amino acids, or bioconjugation schemes to affix organometallic
sites to a protein.14−16
We sought a different approach that would create a small but
consequential perturbation of the composition of native
cofactors. Our strategy was to change only the metal within
the porphyrin IX (PIX) cofactor to minimally perturb the
interaction and structure of the protein−cofactor complex and
therefore leave a nearly native binding site for organic molecules
within the protein. We substituted the biological metal in the
PIX cofactor with metals more commonly employed in classical
organometallic catalytic processes.
Prior to our initial reports, a few groups followed a related
strategy for modifying metalloenzymes in this fashion. For
example, Wantanabe and Lu independently modified the
composition of myoglobin by installing porphyrin-like cofactors
containing manganese in the active site.17−19 Although they
were catalytically active toward sulfoxidation of thioanisole,
these ArMs did not react with high enantioselectivities or with
activities that surpassed those of the natural iron-containing
analogues.18
We proposed that the substitution of noble metals for iron
could increase the activity of the resulting ArMs toward
abiological reactions. If this were true, we would take advantage
of the wide range of hemoproteins, including P450 enzymes, as
hosts for unnatural cofactors containing Ru, Rh, Pd, Ag, and Ir.20
Indeed, the reactivity of these noble−metal ArMs was distinct
from that of the native enzymes.21−23 Increased reaction rates
and selectivities were achieved by directed evolution.
2. INTRAMOLECULAR AND INTERMOLECULAR
INSERTION OF CARBENES INTO C−H BONDS
CATALYZED BY ARMS
2.1. Metal Substitution in Myoglobin for Intramolecular
Carbene Insertion into C−H Bonds
Our goals relied on a facile approach to generate a library of
ArMs comprising porphyrin complexes of noble metals and a
series of heme protein hosts. It is not possible to simply exchange
the iron within the heme ligated to a protein. Thus, a ground-up
synthetic strategy was needed to formally replace iron with other
metals. Procedures have been published for the extraction of
heme from stable proteins such as myoglobin, but these
procedures can be laborious and are not applicable to less
stable heme proteins.24 Therefore, this method was unsuitable
for high-throughput experimentation with noble−metal ana-
logues of most heme proteins. Instead, we generated the
apoprotein and added the noble metal−porphyrin complexes to
them. To do so, we expressed apomyoglobin in media lacking
the δ-aminolevulinic acid required for porphyrin synthesis and
containing low concentrations of iron to minimize the formation
of the Fe−PIX hemoprotein.25 By this protocol, we reliably
expressed and isolated a wide range of mutants of the apo form
of myoglobin. To these apomyoglobins we added a series of
metal−porphyrin cofactors containing Co, Cu, Mn, Rh, Ir, Ru,
and Ag in vitro. In select cases these cofactors contained organic
coligands bound to the noble metals (Figure 1a).20
Other methods can be used to generate these artificial
metalloenzymes without purification of the apoprotein for more
rapid analysis of catalytic activity. For example, recent work from
the Brustad laboratory demonstrated that evolution of a P450
active site in which amino acids sterically inhibit binding of the
Figure 1. (A) Expression of apomyoglobin in minimal medium and
reconstitution with transition metal−PIX cofactors. (B) CD spectra of
the directly expressed apomyoglobin, natively expressed myoglobin,
and directly expressed apomyoglobin reconstituted with heme,
highlighting that the structure of Fe−PIX myoglobin is conserved
regardless of preparation. Adapted with permission from ref 20.
Copyright 2016 Nature Publishing Group.
native heme cofactor leads to higher-yielding in vivo expression
of P450 proteins containing noble metal cofactors possessing a
sterically smaller deuteroporphyrin IX ligand.26 Prior to our
work, heme proteins containing abiological metals for imaging
applications were generated by approaches involving heme
transporters.26−29 As noted at the end of this Account, we simply
expressed the apo form of the protein and added the artificial
cofactors to the resulting cell lysates to generate the ArMs as part
of directed-evolution experiments.
Studies were conducted to assess the structure of the
holoprotein generated from the apoprotein and metal−
porphyrin complexes. We found that the circular dichroism
(CD) spectrum of the native heme-containing myoglobin was
identical to those of the apo form of myoglobin and the
reconstituted heme-containing myoglobin that was prepared by
isolating the apomyoglobin and inserting the Fe−PIX cofactor
(Figure 1b). Moreover, mass spectrometry showed that the
artificially assembled hemoprotein contained a 1:1 stoichiom-
etry of protein to cofactor. Finally, in a particularly revealing
experiment, the enantioselectivities obtained from the cyclo-
propanations of styrene catalyzed by a mutant of myoglobin
expressed in a medium that naturally incorporates heme was the
same as that from the reaction catalyzed by the same mutant
expressed in apo form and reconstituted in vitro with the Fe−
PIX cofactor. This result suggests that the structure of the final
catalyst is independent of how it is prepared.
Having developed a method to generate myoglobins
containing porphyrins bound to a series of metals, we assessed
the reactivities of these potential ArMs toward C−H activation.
A series of myoglobins containing mutations at position H93,
the amino acid residue that ligates to iron at the axial position,
were generated and investigated as catalysts for the insertion of a
carbene unit into the C−H bond of diazoacetate 1 to form chiral
dihydrobenzofuran 2 (Figure 2). The reaction of a carbene
precursor such as a diazo ester with an enzyme to insert a
carbene into a C−H bond is an abiological process and had not
yet been achieved with an ArM or repurposed hemoprotein.30
One can see from Figure 2 that the protein−cofactor assembly
containing iridium in the active site and an axially bound methyl
group attached to the iridium (Ir(Me)) was most active for this
insertion of a carbene into the methoxy C−H bond.
Having observed activity for this C−Hbond functionalization
catalyzed by an ArM, we sought to determine whether directed
evolution could improve the activity and selectivity of the
initially generated constructs. The product obtained from the
first experiments with the wild-type myoglobin and Ir(Me) was
nearly racemic, indicating that the reaction did not occur within
the active site of the protein or that the active site of the protein
was not well-tuned to place the reacting methyl group of the
methoxy substituent on one face of the metal−carbene unit over
the other. To increase the reactivity and stereoselectivity, we
mutated residues H63 and H93 above and below the porphyrin
to hydrophobic amino acids of varying size (Figure 3A). We
then modified residues F43 and V68 to hydrophobic and
alcohol-containing residues. Finally, with the aid of an existing
crystal structure of the wild-type myoglobin, we selected amino
acid residues more distal to the binding site for modification.
After four rounds of evolution, we increased the ee from 0% to
over 80% for formation of one of the two enantiomers and
identified a separate mutant that formed the cyclized product
with 50% ee favoring the opposite enantiomer (Figure 3B).
This library of mutant ArMs catalyzed the insertion of a
carbene unit into the C−H bonds of related substrates
containing a series of groups on the ester (2-Et), at varying
positions of the aromatic ring (4), and into a methylene position
α to oxygen (6) (Figure 3C). In all cases, a mutant that
selectively formed each enantiomer of each product was
identified. These reactions could be achieved with turnover
numbers (TONs) exceeding 7000. In addition to catalyzing
insertions into C−H bonds, these Ir(Me)−myoglobins
catalyzed the cyclopropanation of both internal and terminal
vinylarenes and unconjugated aliphatic α-olefins with good
diastereoselectivity and at least measurable enantioselectivity
without additional rounds of evolution.
Although these ArMs based on myoglobin catalyzed carbene
insertions and cyclopropanations that were unprecedented for
an enzyme, they did have significant limitations. They did not
react with a substrate containing a benzyl group on oxygen, even
though the C−H bond would be weaker than that in the
methoxy group. Moreover, they did not react with substrates
lacking the oxygen atom of the methoxy group, which makes the
methyl C−H bond more electron-rich and weaker than that at
the terminus of an alkyl group. They did react with substantial
enantioselectivity, but the enantioselectivity was not high
enough for practical applications. Finally, although the reactions
occurred with TONs of more than 7000 on a 50 μmol scale,
reactions on a larger 120 μmol scale occurred with TONs closer
to 200. These limitations of the catalytic activity of the ArMs
based on the myoglobin scaffold might be expected because
myoglobin is not an enzyme. The natural biological function of
myoglobin is to bind oxygen, not organic substrates. Therefore,
we envisioned that by following our original experimental design
starting with a P450 enzyme, one of nature’s natural heme-
containing catalysts, we would create ArMs that could catalyze a
wider range of reactions with higher activity and selectivity than
those catalyzed by ArMs from myoglobin.
2.2. Metal Substitution in P450s for Carbene Insertions into
C−H Bonds
Among the many P450s for which crystallographic data are
available, the P450 called CYP119, from Sulfolobus solfataricus,
was the protein from which we constructed mutant iridium-
containing ArMs because this P450 originates from a
thermophilic organism. It seemed plausible that this greater
thermal stability would allow reactions to occur at elevated
Figure 2. Intramolecular insertion of a carbene into a C−H bond to
form a C−C bond (1 → 2) catalyzed by several metal−PIX
reconstituted myoglobins containing the single mutation of the axial
residue.
temperature and that mutants of this enzyme would be more
stable than those of other P450s.31,32
We constructed a mutant library of CYP119 proteins by
following an approach similar to that used to generate the library
of myoglobins. We modified the amino acids proximal and
increasingly more distal to the metal active site,21 making a
conservative change of hydrophobic amino acids for other
hydrophobic amino acids of various sizes. Studies of the
reactivities and selectivities of these artificial P450 enzymes
showed that the resulting enzymes reacted with higher
enantioselectivities in almost all cases and with enantiomeric
ratios (er’s) as high as 97:3 in several cases (Figure 4). In
addition, a P450 mutant was identified that accommodated the
larger size of benzyl ether 7. Moreover, the resulting enzymes
reacted with the unactivated primary C−H bond in the ethyl
group of 8, a substrate lacking the oxygen α to the C−H bond at
which insertion occurred in other substrates.
In addition to improving the intramolecular insertion
reactions, mutants of CYP119 containing the Ir(Me)−PIX
complex catalyzed, for the first time for an enzyme, the
intermolecular insertion of a carbene into a C−H bond. The
intermolecular insertion of a carbene into substrate 10with ethyl
diazoacetate (EDA) occurred in over 60% yield with high
selectivity for insertion over dimerization of the carbene. This
selectivity contrasts with that of the reaction with small-
molecule, transition−metal complexes;33 the reaction catalyzed
by Ir(Me)-CYP119 occurred with ca. 100:1 selectivity for the
C−H insertion over formal dimerization.
In addition to reacting with broader scope and higher
enantioselectivities than ArMs based on myoglobin, the
resulting enzyme reacted with higher TONs and was more
suitable for reactions on a larger scale (Figure 5). For example,
the reaction on a gram scale with less than 0.02 mol % catalyst
formed the insertion product in 55% yield with 92% ee and a
TON of 3235. On a smaller scale the enantioselectivity was
equally high, but the yield was higher (76%) and the TON
exceeded 30 000.
Kinetic studies of the reaction converting 1 to 2 began to
reveal the value of directed evolution, the relationship between
the reactivity of an ArM based on a P450 scaffold (CYP119) and
that of an ArM based on a myoglobin scaffold, and the
relationship between the reactivity of the protein−cofactor
assembly and that of the free Ir(Me)−PIX complex. As shown in
Figure 6, the reaction catalyzed by the free Ir(Me)−PIX
complex was significantly faster than the reaction catalyzed by
the Ir(Me)−myoglobin assembly. Thus, the selectivity of the
myoglobin-based system rests on the stability of the protein−
cofactor complex. Because the free Ir(Me)−PIX generates
racemic product faster than the bound Ir(Me)−PIX forms
enantioenriched product, the generation of free Ir(Me)−PIX
reduces the enantioselectivity. In contrast, the reactivity of the
Ir(Me)−CYP119 assembly was much higher than that of
Ir(Me)−myoglobin and higher than that of the free Ir(Me)−
PIX complex at substrate concentrations lower than those that
saturate the protein. As shown in Figure 7, the catalytic efficiency
of the Ir(Me)−CYP119-Max (C317G, T213G, L69V, V254L)
system is about 2000 times higher than that of the analogous
enzyme derived frommyoglobin.Moreover, the binding of diazo
ester 1 to the P450 system is stronger than it is to the myoglobin
system. This difference in binding was expected on the basis of
the natural functions and substrates of the two hemoproteins.
Less anticipated are the striking differences between the kcat
values of the Ir(Me)−myoglobin system and the Ir(Me)−
CYP119 systems and the large differences in the kcat values of
different mutants even though the cofactor and its methyl ligand
are the same in each protein. Figure 7 shows a plot that places
the kinetic parameters for this reaction in the context of those of
native enzymes involved in the formation of biosynthetic
intermediates and secondary metabolites.34 These data show
that the KM and kcat values of the Ir(Me)−CYP-Max enzyme are
similar to the median KM and kcat values of native enzymes for
their natural substrates.35
Figure 3. (A) Inner-sphere (red), middle-sphere (blue), and outer-sphere (yellow) residues in the active site. (The image of active site and its
surroundings was produced in Chimera from PDB entry 1MBN.30) (B) Evolutionary tree exemplified by showing the enantioselectivies achieved for
the formation of 6. Mutants positioned above the dotted line formed predominantly the opposite enantiomer of those shown below the dotted line.
(C) Additional substrates from the reaction catalyzed by Ir(Me)−myoglobins that form either enantiomer. Adapted with permission from ref 20.
Copyright 2016 Nature Publishing Group.
Figure 4. Variants of Ir(Me)−CYP119 catalyze enantioselective intramolecular and intermolecular C−H carbene insertion reactions (A to E).
Adapted with permission from ref 21. Copyright 2016 American Association for the Advancement of Science.
Figure 5. Intramolecular insertion of the carbene from diazo ester 1
into the methyl C−H bond catalyzed by an Ir(Me)−CYP119
containing the mutations C317G, T213G, L69V, and V254L under
synthetically relevant reaction conditions.
Figure 6. Rates for the intramolecular insertion of a carbene into a C−
H bond to convert diazo ester 1 to dihydrobenzofuran 2 catalyzed by
the free Ir(Me)−PIX cofactor (blue), Ir(Me)−myoglobin (red), and
Ir(Me)−CYP-Max (gray). The reaction conditions are those in Figure
4 with catalyst loadings of 0.025%.
2.3. Insertion of Carbenes into N−H and S−H Bonds with
Noble−Metal ArMs
Following a different approach to the generation of
apomyoglobin, Lehnert and co-workers reported the formal
substitution of Ru(II) for Fe in spermwhale myoglobin.36 These
reconstituted Ru−PIX myoglobin systems catalyzed the
insertion of carbenes into the N−H bonds of aniline and aniline
derivatives. Specifically, these Ru-ArMs catalyzed the reaction of
EDAwith aniline with TONs greater than 500. Furthermore, the
reaction of EDA with aniline derivatives containing both
electron-withdrawing and electron-donating groups, such as 4-
trifluoromethylaniline (TON = 451), 4-nitroaniline (TON =
29), 4-methoxyaniline (TON = 57), and 4-methylaniline (TON
= 358), were catalyzed by the single Ru−PIX myoglobin mutant
H64A. These Ru-ArMs were shown to catalyze the insertions of
the carbene from EDA into N−H bonds over additions to the
CC bond of 4-vinylaniline with perfect chemoselectivity.
Contemporaneous with the work of Lehnert, Fasan and co-
workers reported the application of myoglobins containing
noble−metal cofactors for the insertion of carbenes into N−H
bonds and S−H bonds.29 Using a double mutant of sperm whale
myoglobin (H64V and V68A), they generated ArMs housing
porphyrins bound to Ru(CO), Rh, and Ir(Me) units. Using
these ArMs, they reported the insertion of the carbene from
EDA into the N−H bond of aniline with moderate TONs (as
high as 168 in the case of the Ir(Me)-ArM). In the same paper,
Fasan and co-workers also reported the reaction of thiophenol
with EDA catalyzed by mutants of myoglobin. The iron
hemoproteins catalyzed this carbene insertion into S−H
bonds with TONs of 985. Myoglobin mutants reconstituted
with metalloporphyrins containing Ru(CO) (TON = 795), Rh
(TON = 95), and Ir(Me) (TON > 1000) also catalyzed this
insertion reaction. It is clear from this work that the substitution
of a noble metal for iron does not always generate a more active
catalyst and is not required for all organic transformations. Also
included in Fasan’s report are the cyclopropanation of styrene
and the intermolecular insertion of a carbene into a C−H bond
catalyzed by an Ir(Me)−myoglobin construct.
3. CYCLOPROPANATION OF BOTH TERMINAL AND
INTERNAL OLEFINS CATALYZED BY
NOBLE−METAL ARMS
In addition to catalyzing the insertion of carbenes into C−H
bonds, our group’s Ir(Me)−CYP119 mutants catalyzed the
cyclopropanation of alkenes, including internal, unconjugated
alkenes. Reactions of alkenes that occur in low yield with low
TONswhen catalyzed by iron-based enzymes occur in high yield
with high TONs when catalyzed by the Ir(Me)-ArM systems.
For example, Ir(Me)-ArMs catalyze the cyclopropanation of
both internal and terminal vinylarenes, unactivated α-olefins,
and internal, unconjugated olefins, and they do so with good
diastereoselectivity and enantioselectivity.22
Figure 7. (A) Model reaction converting 1 to 2. (B) Enantioselectivities and yields for the formation of 2 catalyzed by evolved variants of CYP119
(0.17% catalyst loading, 10 mM substrate). (C) Kinetic parameters for the formation of 2 by variants of CYP119 (0.1 mol % catalyst loading, 5 mM
substrate). For free Ir(Me)−PIX, k1 (the first-order kinetic constant) is listed instead of kcat/KM. The inset shows the dependence of the turnover
frequency (TOF) on [1]0 for reactions conducted with 0.005 mM catalyst. (D, E) Comparison of KM and kcat values for CYP119-Max with those of
natural enzymes involved in the metabolism of intermediate and secondary metabolites; for comparison, the kinetic parameters of an Ir(Me)−PIX
myoglobin catalyzing the same transformation are shown. Adapted with permission from ref 21. Copyright 2016 American Association for the
Advancement of Science.
Our studies to investigate the activity of the Ir(Me)-
containing ArMs as catalysts for cyclopropanation were initiated
with the library of mutants that we studied for carbene insertion
into C−H bonds (see section 2.2). An assessment of the
reactivity of these ArMs showed that the products were formed
with varying diastereoselectivity and enantioselectivity. Just one
additional round of directed evolution produced enzymes that
catalyzed the cyclopropanation of styrene with EDA to give
either enantiomer of 15 with nearly perfect enantioselectivity,
high cis:trans diastereoselectivity, high yields, and TONs in the
range of 10 000 (Figure 8). The cis:trans selectivity observed for
the cyclopropanation of styrene catalyzed by the Ir(Me)−P450
assembly contrasts with the selectivity of the same reaction
catalyzed by the free Ir(Me)−PIX cofactor. The reaction
catalyzed by the Ir(Me)−P450 assembly forms the cis isomer as
the major product, but the free cofactor forms the trans isomer
as the major product. The cyclopropanations of the 1,1-
disubstituted vinylarene (α-methylstyrene) with EDA catalyzed
by these Ir(Me)-ArMs also occurred to form either enantiomer
of 17 as the major enantiomer and the cis product as the major
diastereomer. The TONs for reaction of α-methylstyrene were
240 to 500.
Reactions of internal alkenes also occurred with high
enantioselectivities and diastereoselectivities. The reactions of
the two isomers of β-methylstyrene gave distinct isomeric
products. cis-β-Methylstyrene reacted to give either enantiomer
of cis diastereomer 19 with TONs between 250 and 300. This
diastereomer is the same as that formed by the free Ir(Me)−PIX
cofactor. trans-β-Methylstyrene also reacted to give product 21
with high enantioselectivity and diastereoselectivity. In this case,
the diastereoselectivity depended on the mutant, in one case
favoring the isomer with the aryl substituent cis and the methyl
substituent trans to the ester group with 30:1 selectivity and in
another case favoring the isomer with the aryl substituent trans
and the methyl group cis to the ester group with 6:1 selectivity.
The free Ir(Me)−PIX complex favored the formation of the
latter diastereomer, indicating that the active site can reverse the
stereoselectivity of this process. Additional rounds of directed
evolution would likely increase the stereoselectivities and TONs
of these reactions.
These ArMs also catalyzed the first enzyme-catalyzed
cyclopropanations of an unconjugated terminal alkene (23)
and an unconjugated internal alkene (25). Although cyclo-
propanations of two nitrile-substituted internal vinylarenes
catalyzed by a mutant of native myoglobin have been claimed
recently, the TONs were based on conversion (2−5%), and the
yields were not determined.37 The reaction of allylacetone
catalyzed by two different mutants of Ir(Me)−CYP119 gave
Figure 8. Addition of EDA to terminal and internal olefins catalyzed by variants of Ir(Me)−PIX−CYP119 and Ir(Me)−PIX.
either enantiomer of the cyclopropane product with nearly
perfect enantioselectivity of the cis diastereomer (27). The
TONs ranged from 440 for one enantiomer to over 1000 for the
other. The reactions of unconjugated internal alkenes are a
particular challenge because of the greater HOMO−LUMO gap
and unfavorable steric properties for approach to the catalyst.
Nevertheless, a mutant of the Ir(Me)-ArM catalyzed the
cyclopropanation of cyclic unconjugated internal alkenes. As a
representative example, methyl cyclopentene-4-carboxylate
reacted to give one of four stereoisomers of cyclopropane 29
with over 200:1 selectivity and greater than 1000 turnovers.
We envisioned in the long term that these kinds of enzymes
can be used as parts of biosynthetic pathways. Thus, we
investigated whether the kinds of alkenes that are the products of
biosynthesis, such as unsaturated terpenes, would be amenable
to cyclopropanation. Indeed, β-pinene (30), limonene (40), and
carvone (42) all underwent cyclopropanation at the uncon-
jugated disubstituted alkene (Figure 9). Studies to increase the
TONs for the cyclopropanation of terpenes catalyzed by our
Ir(Me)−CYP119 constructs are ongoing.
Although much of the work reported here focuses on
stereoselectivity, we are equally interested in control of the
regioselectivity and site selectivity. An initial experiment to
assess whether such selectivities could be achieved involved a
competition between 1-octene (22) and cis-2-octene (24)
(Figure 10). The free Ir(Me)−PIX cofactor strongly favors
cyclopropanation of the terminal alkene to give a 9:1 ratio of the
cyclopropane derived from 1-octene over that derived from cis-
2-octene. However, a mutant of CYP119 was identified that
forms the cyclopropane derived from cis-2-octene in preference
to that derived from 1-octene. This result indicates that ArMs
can be evolved for a wide range of selectivities, even in the
absence of functional groups that could interact with the amino
acid side chains in the substrate binding site.
4. INTRAMOLECULAR INSERTION OF NITRENES INTO
C−H BONDS
The Ir(Me)-ArMs also catalyze enantioselective aminations of
C−H bonds. Directed evolution of hemoproteins has created
iron-containing enzymes that catalyze C−H amination with
good TONs.4,38 However, these iron-containing enzymes
required significant bioengineering (more than nine mutations)
to reach the desired reactivity, in part because of the low
chemoselectivity of the heme unit for the insertion of a nitrene
into a C−H bond over the reduction of the sulfonyl azide to the
sulfonamide. In comparison, amination catalyzed by Ir(Me)-
ArMs occurred with similar TONs but required fewer mutations
to the P450 scaffold to achieve nitrene insertion over azide
reduction because of the inherent selectivity of the Ir(Me)
cofactor for nitrene insertion over azide reduction.23
Figure 11 shows the products from nitrene insertions into
secondary and tertiary benzylic and non-benzylic C−H bonds
catalyzed by Ir(Me)-ArMs and the selectivities of these reactions
for insertion of the nitrene unit into a C−H bond versus
reduction of the azide. These data show that several azides
reacted without formation of the reduced sulfonamide by-
product and formed the product from intramolecular nitrene
insertion in yields of up to 98%. The products shown in Figure
11a from the intramolecular insertion of the nitrene unit into C−
Hbonds were formed with TONs exceeding 100 with up to 95:5
er. A survey of nitrene insertions catalyzed by a series of
metalloporphyrins is shown in Figure 11b. This graph shows the
high inherent selectivity of the Ir(Me)−PIX cofactor for the
formation of the product from nitrene insertion into a C−H
Figure 9.Cyclopropanation reactions of natural terpenes and their derivatives. For cases in which the TONs for the remaining terpenes are not given,
the TONs were ≤20.
Figure 10. Substrate-selective cyclopropanation catalyzed by a variant
of CYP119 in comparison with the same reaction catalyzed by the free
cofactor. The amounts of 23 and 25 are the sums of all stereoisomers of
the product. The reaction conditions and stereoselectivities are
reported in ref 22
bond over that from reduction of the azide. Further studies of
nitrene insertion are ongoing in our laboratory.
5. OUTLOOK AND CONCLUSIONS
The studies described in this Account point toward many future
directions that would exploit the high chemoselectivity,
regioselectivity, and stereoselectivity of ArMs for the synthesis
of organic molecules. Much work must be done to show that
ArMs can be used on large scales and to devise ways in which
ArMs can be assembled in whole cells and used as both purified
proteins and in whole-cell systems. However, the wide range of
P450s with binding sites predisposed for specific large or small
molecules and the known P450s that bind indiscriminately to
organic molecules can be used as hosts following the strategies
outlined in this Account. Moreover, one can envision that these
ArMs could be used to intersect intermediates along
biosynthetic pathways to catalyze unnatural transformations
prior to the full processing of the intermediates to form the final
biosynthetic product. Finally, cofactors that are distinct from
porphyrin complexes can be envisioned that would create
enzymes that catalyze processes with a scope beyond the group
transfer reactions catalyzed by metalloporphyrin systems. These
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(9) Narayan, A. R. H.; Jimeńez-Oseś, G.; Liu, P.; Negretti, S.; Zhao,
W.; Gilbert, M. M.; Ramabhadran, R. O.; Yang, Y.-F.; Furan, L. R.; Li,
Z.; Podust, L. M.; Montgomery, J.; Houk, K. N.; Sherman, D. H.
Enzymatic hydroxylation of an unactivated methylene C−H bond
guided by molecular dynamics simulations. Nat. Chem. 2015, 7, 653−
660.
(10) Loskot, S. A.; Romney, D. K.; Arnold, F. H.; Stoltz, B. M.
Enantioselective Total Synthesis of Nigelladine A via Late-Stage C−H
Oxidation Enabled by an Engineered P450 Enzyme. J. Am. Chem. Soc.
2017, 139, 10196−10199.
(11) Thomas, C. M.; Ward, T. R. Artificial metalloenzymes: proteins
as hosts for enantioselective catalysis. Chem. Soc. Rev. 2005, 34, 337−
346.
(12) Heinisch, T.; Ward, T. R. Artificial Metalloenzymes Based on the
Biotin−Streptavidin Technology: Challenges and Opportunities. Acc.
Chem. Res. 2016, 49, 1711−1721.
(13) Jeschek, M.; Reuter, R.; Heinisch, T.; Trindler, C.; Klehr, J.;
Panke, S.; Ward, T. R. Directed evolution of artificial metalloenzymes
for in vivo metathesis. Nature 2016, 537, 661−665.
(14) Lewis, J. C. Metallopeptide catalysts and artificial metal-
loenzymes containing unnatural amino acids. Curr. Opin. Chem. Biol.
2015, 25, 27−35.
(15) Upp, D. M.; Lewis, J. C. Selective C−H bond functionalization
using repurposed or artificial metalloenzymes. Curr. Opin. Chem. Biol.
2017, 37, 48−55.
(16) Drienovska,́ I.; Alonso-Cotchico, L.; Vidossich, P.; Lledoś, A.;
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